As of November 14, 2026, Personalis, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 17, 2026 (Form 8-K, March 17, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Personalis, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Personalis, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-17. Every row below is cited to the filing it comes from, and this page adds each new change as Personalis, Inc. files it.
Also on the record for Personalis, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 6.67% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Ameriprise Financial, Inc. | 5.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 3.82% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.9% of the class | 5%+ stakes | Source |
| July 21, 2026 | Stake report, Schedule 13D/A, by Tempus AI, Inc. | 12.6% of the class | 5%+ stakes | Source |
| June 10, 2026 | Stake report, Schedule 13D/A, by Lightspeed Venture Partners Select IV, L.P. | 2% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by Deep Track Capital, LP | 5.51% of the class | 5%+ stakes | Source |
| April 8, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 4.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Ameriprise Financial, Inc. | 7.1% of the class | 5%+ stakes | Source |
| January 29, 2026 | Stake report, Schedule 13G/A, by Orin Hirschman | 3.8% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 12.1% of the class | 5%+ stakes | Source |
| September 12, 2025 | Stake report, Schedule 13D/A, by Tempus AI, Inc. | 14.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Personalis, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Personalis, Inc. and the records around it.
Personalis, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- ARK Investment Management LLC also filed stake reports on 23 other companies: Beam Therapeutics Inc. (Nov 2026), CERUS CORP (Nov 2026), CRISPR Therapeutics AG (Nov 2026)
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 60 other companies: Mentari Therapeutics, Inc. (Nov 2026), Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026)
Watch Personalis, Inc.
Get an email when Personalis, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Personalis, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Personalis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Personalis, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-17 | Reported | not named in the filing | 8-K, 2026-03-17 |
New leaders reset buying decisions — get the Full Report on Personalis, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Personalis, Inc., with the record behind each one.
Find candidates like senior executive at Personalis, Inc.Every change, in the filing's words
Reported
On March 13, 2026, the board of directors (the "Board") of Personalis, Inc. (the "Company"), based in part on the recommendation of Christopher Hall, the Company's Chief Executive Officer, appointed Richard Chen as the Company's President, in addition to his roles as the Company's Executive Vice President, R&D, and Chief Medical Officer.
- Dr. Chen, age 55, has served as the Company's Executive Vice President, R&D, since March 2023 and as Chief Medical Officer since July 2021.
- Before that, he served as the Company's Senior Vice President, R&D from July 2021 to March 2023 and Chief Scientific Officer from November 2011 to July 2021.
- Since September 2011, Dr. Chen has served on the clinical faculty at Stanford University School of Medicine.
- In August 1997, Dr. Chen co-founded Ingenuity Systems, a genomic data software company.
- Dr. Chen holds a B.S. in Computer Science from Stanford University, an M.S. in Medical Informatics from Stanford University School of Medicine, and an M.D. from Stanford University School of Medicine.
- In connection with his appointment as the Company's President, Dr. Chen's annual base salary will be increased to $570,000, effective April 1, 2026, and his performance bonus target has been increased to 70% of his then-current annual base salary.
- The foregoing equity awards will be granted under the Company's 2019 Equity Incentive Plan.
Tools for this story
Each opens in a new tab, filled in for Personalis, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
